Citizen Petition from Alliance to Protect Insulin Choice

Scott Strumello, a long-term patient with Type 1 diabetes, supports the petition by highlighting the negative impact of pharmaceutical companies discontinuing effective insulin products like Levemir. He argues that these discontinuations are driven by commercial interests rather than safety concerns and criticizes the FDA for delays in implementing policies to facilitate biosimilar competition.

The commenter, a long-term Type 1 Diabetes patient, supports the petition by expressing frustration over the high costs and poor efficacy of current insulin options compared to older, more affordable products. They specifically request the return of Levemir and a resolution to the pricing issues caused by insulin manufacturers.

Dr. Emily King, a pediatric specialist, supports the petition to protect access to Levemir. She explains that her 2-year-old patient requires this specific long-acting insulin due to high sensitivity.